OncoMatch/Clinical Trials/NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Is NCT06717347 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for diffuse large b-cell lymphoma.
Treatment: Zilovertamab vedotin · Rituximab · Cyclophosphamide · Doxorubicin · Rituximab Biosimilar · Prednisone · Prednisolone · Vincristine · Rescue medication — The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Excluded: Stage ANN ARBOR STAGE I
Has Ann Arbor Stage I DLBCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Cardiac function
ejection fraction ≥45% as determined by either echocardiogram (echo) or multigated acquisition (muga)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center ( Site 0165) · Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) · Phoenix, Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0124) · Tucson, Arizona
- Providence Medical Foundation-Oncology ( Site 0168) · Fullerton, California
- Cancer Blood and Specialty Clinic ( Site 0109) · Los Alamitos, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify